WALTHAM, Mass., Feb. 25, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has commenced an underwritten public offering of $75 million of its common stock. In connection with this offering, TESARO plans to grant the underwriters an option to purchase up to an additional $11,250,000 shares of its common stock to cover over-allotments. Citigroup and Morgan Stanley are acting as joint book-running managers for the offering with Leerink Swann, Deutsche Bank Securities, BMO Capital Markets and Baird acting as co-managers for the offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The offering will be made by TESARO pursuant to a registration statement on Form S-1 previously filed with the Securities and Exchange Commission (SEC). A preliminary prospectus related to the offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov. Copies of the preliminary prospectus relating to this offering may be obtained from Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via telephone at 1-800-831-9146 or email at firstname.lastname@example.org.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor will there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or other jurisdiction.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties, including statements regarding the proposed public offering. More information about potential factors that could affect TESARO's business and financial results is contained in its annual report on Form 10-K filed with the SEC. The Company does not intend, and undertakes no duty, to update this information to reflect future events or circumstances.
TESARO, Inc. is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.